Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Johnson & Johnson, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Turnover Ratios
Inventory turnover 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Receivables turnover 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Payables turnover 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Working capital turnover 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Average No. Days
Average inventory processing period 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Add: Average receivable collection period 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Operating cycle 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Less: Average payables payment period 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Cash conversion cycle 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

The financial ratios and periods analyzed reveal several trends in the company's operational efficiency and liquidity management over the reported quarters. These metrics provide insights into inventory management, receivables and payables effectiveness, and the overall cash conversion process.

Inventory Turnover
The inventory turnover ratio shows a gradual decline over the periods, starting from a peak around 3.04 and tapering down to approximately 2.24 by the latest quarter. This suggests that inventory is being cycled through less frequently over time, possibly indicating a slower sales pace or increased inventory levels.
Receivables Turnover
The receivables turnover ratio has fluctuated modestly but generally maintains a range around 5.3 to 6.1, indicating relatively stable efficiency in collecting receivables. Some decline is noted in recent quarters, potentially suggesting a slight relaxation in credit collection efforts or longer customer payment terms.
Payables Turnover
This ratio displays variability but remains roughly within a 2.6 to 3.3 range. There is no clear upward or downward trend, implying that the company has relatively consistent payment patterns to suppliers. Occasional dips in payables turnover could indicate temporary elongation of payment times to vendors.
Working Capital Turnover
The working capital turnover ratio demonstrates notable volatility. Initial values decline significantly from above 9 to about 4.88 before showing sharp spikes around 23.02 and 58.86 and then reverting to more moderate levels near 6.1. This inconsistency may reflect fluctuating sales in relation to working capital or irregularities in operational efficiency.
Average Inventory Processing Period
There is a consistent increase in the average inventory processing period, starting near 120 days and rising steadily to about 163 days. This lengthening of the inventory processing cycle could indicate slower inventory movement and potential overstocking concerns.
Average Receivable Collection Period
The average collection period for receivables shows slight variability, generally fluctuating between 59 and 68 days. Recent periods indicate a marginal lengthening, which may suggest relaxed credit terms or slower customer payments.
Operating Cycle
The operating cycle lengthens over time, moving from approximately 180 days to about 228 days. This trend is consistent with the increase in inventory processing and receivables collection periods, indicating a longer time span between acquisition of inventory and cash receipt from sales.
Average Payables Payment Period
The average payables payment period exhibits fluctuations without a clear directional trend, ranging mostly between 108 and 137 days. Occasional elongation of payment periods suggests strategic management of cash outflows but without persistent extension.
Cash Conversion Cycle
The cash conversion cycle varies notably between periods, generally ranging from about 51 to 116 days. The data shows episodes of both improvement and deterioration in how quickly cash is converted back from operations, reflecting variable efficiency in working capital management.

Overall, the data suggests a trend of increasing operating cycle duration driven by longer inventory holding and marginally slower receivable collections. While payables management remains relatively stable, the company's ability to efficiently convert investments in working capital into cash shows fluctuation. This indicates areas where operational improvements and tighter working capital management could enhance liquidity and efficiency over time.


Turnover Ratios


Average No. Days


Inventory Turnover

Johnson & Johnson, inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Cost of products sold 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598 7,955 7,250 7,587 7,063 7,814 6,972 6,579 7,062
Inventories 12,659 12,444 12,603 12,169 11,383 11,181 11,198 12,888 12,809 12,483 11,675 11,437 10,990 10,387 10,387 10,100 9,952 9,344 9,599 9,424 8,868
Short-term Activity Ratio
Inventory turnover1 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Amgen Inc. 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58
Bristol-Myers Squibb Co. 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68
Danaher Corp. 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Eli Lilly & Co. 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38
Gilead Sciences Inc. 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72
Merck & Co. Inc. 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45
Pfizer Inc. 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08
Regeneron Pharmaceuticals Inc. 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58
Thermo Fisher Scientific Inc. 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02
Vertex Pharmaceuticals Inc. 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Inventory turnover = (Cost of products soldQ1 2025 + Cost of products soldQ4 2024 + Cost of products soldQ3 2024 + Cost of products soldQ2 2024) ÷ Inventories
= (7,357 + 7,128 + 6,963 + 6,869) ÷ 12,659 = 2.24

2 Click competitor name to see calculations.

Cost of Products Sold
The cost of products sold demonstrates variability over the periods analyzed. Beginning at 7,062 million US dollars in March 2020, it experienced a slight decline to 6,579 million by June 2020, followed by fluctuations with notable peaks around December of each year. The highest costs are observed near year-end 2020 (7,814 million) and year-end 2021 (7,955 million). There is a downward trend from April 2023 (6,687 million) through July 2023 (6,462 million), but the figures subsequently rise again into 2024 and early 2025, culminating at 7,357 million in March 2025. Overall, the cost of products sold shows seasonal increases toward year ends with recurring fluctuations throughout the analyzed timeframe.
Inventories
Inventories exhibit a general upward trend over the entire period. Starting from 8,868 million US dollars in March 2020, there is a consistent increase with some acceleration noticeable during late 2022 and early 2023, reaching a peak of 12,888 million in July 2023. After a brief dip in October 2023 to 11,198 million, inventories rise again through 2024, reaching 12,659 million by March 2025. This pattern suggests expanding stock levels with minor short-term reductions, indicative of possible inventory build-up strategies or changes in inventory management.
Inventory Turnover Ratio
The inventory turnover ratio, reported starting in September 2020, displays a declining trend over the periods observed. Initially recorded at 3.04, the ratio gradually decreases through subsequent quarters, moving below 2.5 by the end of 2022 and continuing downward to around 2.2 by late 2024. This decline in turnover ratio implies a lengthening inventory holding period, suggesting that inventory is being sold less frequently throughout the year. This trend may point to slower sales or increased inventory accumulation relative to cost of goods sold, requiring further monitoring for potential impacts on working capital efficiency.

Receivables Turnover

Johnson & Johnson, receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Sales to customers 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426 24,804 23,338 23,312 22,321 22,475 21,082 18,336 20,691
Accounts receivable, trade, less allowances 16,020 14,842 16,174 15,794 14,946 14,873 14,798 16,777 16,350 16,160 15,890 16,139 15,594 15,283 14,911 14,871 14,938 13,576 14,579 14,645 14,874
Short-term Activity Ratio
Receivables turnover1 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Amgen Inc. 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36
Danaher Corp. 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Eli Lilly & Co. 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18
Gilead Sciences Inc. 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98
Merck & Co. Inc. 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11
Pfizer Inc. 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28
Regeneron Pharmaceuticals Inc. 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07
Thermo Fisher Scientific Inc. 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61
Vertex Pharmaceuticals Inc. 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Receivables turnover = (Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024 + Sales to customersQ2 2024) ÷ Accounts receivable, trade, less allowances
= (21,893 + 22,520 + 22,471 + 22,447) ÷ 16,020 = 5.58

2 Click competitor name to see calculations.

The analyzed financial data reveals several notable trends in sales, accounts receivable, and receivables turnover over the indicated periods.

Sales to customers
Sales figures exhibit some volatility with a general pattern of fluctuations across quarters. There was an initial decline from 20,691 million USD in March 2020 to 18,336 million USD in June 2020, followed by a recovery and peak at 24,804 million USD by December 2021. Subsequently, sales declined notably in early 2023, reaching a low of 20,894 million USD in April 2023. After that, sales trends stabilized with smaller oscillations, ending at 21,893 million USD in March 2025. Overall, the sales trend reflects cyclic variations with recovery periods and intermittent slowdowns.
Accounts receivable, trade, less allowances
The accounts receivable balance increased gradually over the observed period. Starting at 14,874 million USD in March 2020, it saw minor dips but generally rose to a high point of 16,774 million USD in July 2023. After slight decreases in the subsequent periods, it again increased to reach 16,020 million USD by March 2025. This upward movement suggests a consistent accumulation of receivables, potentially linked to increased credit sales or elongated collection periods.
Receivables turnover ratio
The receivables turnover ratio shows a gradual downward trend from 6.08 in September 2020 to a minimum of 5.36 in April 2023, implying a slower conversion of receivables into cash over time. After this low point, the ratio exhibits slight improvement and stabilization around the mid-5 range, fluctuating between 5.42 and 5.98 in the last recorded periods. The reduction from earlier higher levels points to potential challenges in collections or changes in credit policy.

In summary, while sales have experienced oscillations with periods of growth and decline, accounts receivable have steadily increased, which has contributed to a declining trend in receivables turnover. This confluence may indicate longer collection cycles or more lenient credit terms affecting cash flow efficiency.


Payables Turnover

Johnson & Johnson, payables turnover calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Cost of products sold 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598 7,955 7,250 7,587 7,063 7,814 6,972 6,579 7,062
Accounts payable 9,545 10,311 8,954 8,848 8,174 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309 11,055 8,961 8,704 8,503 9,505 7,044 6,765 7,411
Short-term Activity Ratio
Payables turnover1 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65 4.72 5.41 4.92 4.40 4.33
Bristol-Myers Squibb Co. 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34
Danaher Corp. 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Eli Lilly & Co. 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24 4.38 4.46 4.30 3.75 3.41
Gilead Sciences Inc. 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43 9.36 9.18 8.70 8.71 5.42
Merck & Co. Inc. 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25 2.96 4.54 3.93 3.81 3.37
Pfizer Inc. 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66 5.53 5.11 3.72 2.68 2.02
Regeneron Pharmaceuticals Inc. 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39 4.32 4.23 3.42 2.23 2.36
Thermo Fisher Scientific Inc. 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96 6.83 8.31 8.88 8.12 7.45
Vertex Pharmaceuticals Inc. 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Payables turnover = (Cost of products soldQ1 2025 + Cost of products soldQ4 2024 + Cost of products soldQ3 2024 + Cost of products soldQ2 2024) ÷ Accounts payable
= (7,357 + 7,128 + 6,963 + 6,869) ÷ 9,545 = 2.97

2 Click competitor name to see calculations.

Cost of products sold
The cost of products sold exhibits a pattern of fluctuations over the observed periods. Initially, there is a decline from March 2020 through June 2020, followed by a rise peaking toward December 2020. Subsequent quarters show a repeating pattern of increases and decreases, with notable decreases during mid-2023, particularly from April to October. The overall trend from early 2023 to the end of 2024 is relatively stable with minor oscillations, though the values marginally increase again in the last reported quarters through March 2025.
Accounts payable
Accounts payable values display notable volatility with significant peaks and troughs. There is a strong upward trend from March 2020 to December 2020, where the values rise sharply. After a correction early in 2021, the payable amounts increase again toward the end of 2021 and continue to peak in multiple quarters thereafter. The pattern indicates sporadic increases, particularly at the end of calendar years, with some moderation in mid-year figures. The data suggests periodic accumulation and settlement cycles, with the highest values seen in late 2022 and mid-2024.
Payables turnover ratio
The payables turnover ratio, available only from December 2020 onwards, demonstrates variability without a consistent directional trend. Ratios oscillate between approximately 2.66 and 3.38, indicating fluctuations in how frequently accounts payable are settled relative to cost of goods sold. Higher ratio values generally signify quicker payments. Periods such as mid-2021 and early 2022 reflect relatively higher turnover, whereas ratios toward the end of 2023 and early 2024 indicate slower turnover. Overall, the ratio suggests inconsistent payment pacing with alternating quarters of acceleration and deceleration in payables settlement.
Summary insights
The data reveals that cost of products sold and accounts payable do not move entirely in tandem. While cost of products sold shows moderate cyclicality, accounts payable values have more pronounced fluctuations, implying varying credit terms or payment scheduling practices. The payables turnover ratio corroborates this, reflecting irregular payment patterns over time. Such variation may arise from strategic supplier negotiations, inventory management decisions, or external economic influences impacting procurement and cash flow management.

Working Capital Turnover

Johnson & Johnson, working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Current assets 71,551 55,893 53,249 57,817 57,002 53,495 53,703 60,567 64,388 55,294 65,236 63,847 60,424 60,979 59,889 53,769 52,533 51,237 57,578 45,892 44,226
Less: Current liabilities 56,903 50,321 51,759 53,933 48,725 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390 45,226 44,561 38,721 40,932 42,493 38,847 36,772 33,689
Working capital 14,648 5,572 1,490 3,884 8,277 7,213 9,333 6,397 4,015 (508) 19,693 19,026 17,034 15,753 15,328 15,048 11,601 8,744 18,731 9,120 10,537
 
Sales to customers 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426 24,804 23,338 23,312 22,321 22,475 21,082 18,336 20,691
Short-term Activity Ratio
Working capital turnover1 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12
Amgen Inc. 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55
Bristol-Myers Squibb Co. 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72
Danaher Corp. 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Eli Lilly & Co. 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93
Gilead Sciences Inc. 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30
Merck & Co. Inc. 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83
Pfizer Inc. 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58
Regeneron Pharmaceuticals Inc. 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20
Thermo Fisher Scientific Inc. 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76
Vertex Pharmaceuticals Inc. 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Working capital turnover = (Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024 + Sales to customersQ2 2024) ÷ Working capital
= (21,893 + 22,520 + 22,471 + 22,447) ÷ 14,648 = 6.10

2 Click competitor name to see calculations.

Working Capital
The working capital exhibits notable fluctuations over the analyzed periods. Starting from a moderate value around 10,537 million US dollars in March 2020, it declined to 9,120 million by June 2020, then sharply increased to 18,731 million by September 2020. A significant drop to 8,744 million was observed at the end of 2020. In 2021, working capital steadily rose, peaking at 19,693 million in October but dramatically turned negative to -508 million by the end of 2022. From 2023 onward, there is a recovery trend with values oscillating between 1,490 and 9,333 million, culminating in a substantial increase to 14,648 million by March 2025. This pattern suggests periods of volatility and possible inventory or receivables management changes, with a marked anomaly at the end of 2022.
Sales to Customers
Sales figures demonstrate relative stability with minor variances across the quarters. Beginning at 20,691 million US dollars in early 2020, sales dipped slightly in mid-2020 but recovered by December 2020 to around 22,475 million. During 2021, a gradual increase was evident, reaching a peak near 24,804 million in the last quarter. The sales plateaued and experienced some modest fluctuations between approximately 21,394 million and 22,471 million from 2023 onwards. The overall sales trend indicates resilience with no substantial growth or decline, reflecting consistent customer demand.
Working Capital Turnover
The working capital turnover ratio, available intermittently, reveals variable operational efficiency in utilizing working capital to generate sales. The ratio was relatively high, peaking at 9.44 in December 2020 but generally decreasing through 2021 to a low near 4.88 in October 2022. An anomalous spike to 23.02 was noted shortly thereafter, followed by oscillations with occasional very high values such as 58.86 in late 2024. These sharp increases correspond with periods of low or negative working capital, indicating that sales were generated from a relatively smaller base of working capital during those times. The volatility in this ratio suggests fluctuations in asset management policies and possible short-term liquidity challenges.
Overall Insights
The financial data reflects a company experiencing operational and working capital management challenges, particularly highlighted by the abrupt negative working capital at the end of 2022. Sales remained fairly stable throughout the periods, which points to consistent market performance despite internal liquidity and asset management variations. The irregularity and spikes in the working capital turnover ratio imply shifts in the efficiency of working capital usage, impacted heavily by the fluctuating base of working capital. Ongoing monitoring and management focus on working capital controls would be advisable to stabilize these metrics and ensure operational fluidity.

Average Inventory Processing Period

Johnson & Johnson, average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Inventory turnover 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Short-term Activity Ratio (no. days)
Average inventory processing period1 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Amgen Inc. 195 199 209 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231
Bristol-Myers Squibb Co. 69 67 102 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64
Danaher Corp. 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Eli Lilly & Co. 379 329 349 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265
Gilead Sciences Inc. 103 100 101 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134
Merck & Co. Inc. 150 147 149 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149
Pfizer Inc. 229 222 219 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338
Regeneron Pharmaceuticals Inc. 582 572 573 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625
Thermo Fisher Scientific Inc. 76 72 79 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91
Vertex Pharmaceuticals Inc. 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.24 = 163

2 Click competitor name to see calculations.

Inventory Turnover Ratio
The inventory turnover ratio demonstrates a declining trend over the period analyzed. Beginning at approximately 3.04 in the earliest available quarter, the ratio steadily decreases to values around 2.15 to 2.24 in the most recent quarters. This decline suggests a slowing pace in the rate at which inventory is sold and replaced.
Average Inventory Processing Period
Correspondingly, the average inventory processing period, expressed in days, shows an upward trend across the same timeframe. Starting from 120 days, the period increases progressively, reaching values exceeding 160 days in recent quarters. This increase indicates that inventory remains in stock for longer durations before being sold or utilized.
Relationship and Implications
The inverse relationship between inventory turnover and inventory processing period is evident, with turnover decreasing as the processing period lengthens. This dynamic may suggest less efficient inventory management or changing market conditions affecting the speed of inventory movement. It could also reflect strategic decisions such as increasing safety stock or adjustments due to supply chain constraints.
Overall Assessment
Overall, the data reveals a clear shift toward slower inventory turnover and extended inventory holding periods over the observed quarters. This trend warrants further examination to understand underlying factors and potential impacts on liquidity, operational efficiency, and working capital management.

Average Receivable Collection Period

Johnson & Johnson, average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Receivables turnover 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Short-term Activity Ratio (no. days)
Average receivable collection period1 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Amgen Inc. 91 77 86 86 88 99 88 84 84 82 79 79 76 74 71 68 67 68
Danaher Corp. 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Eli Lilly & Co. 90 89 92 103 80 97 93 93 99 88 84 80 79 86 78 80 80 87
Gilead Sciences Inc. 56 56 59 62 62 63 64 57 57 65 59 55 51 61 61 58 57 73
Merck & Co. Inc. 62 58 66 68 68 63 64 69 66 58 59 62 66 69 66 61 65 60
Pfizer Inc. 69 66 87 74 72 69 58 48 48 40 59 55 52 52 63 70 78 69
Regeneron Pharmaceuticals Inc. 144 160 161 155 146 158 156 148 151 160 148 132 107 137 147 206 166 177
Thermo Fisher Scientific Inc. 72 70 71 68 68 70 70 67 66 66 63 66 70 74 52 52 56 65
Vertex Pharmaceuticals Inc. 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.58 = 65

2 Click competitor name to see calculations.

Receivables Turnover Ratio
The receivables turnover ratio shows moderate fluctuations over the observed quarters. Starting at 6.08 in March 29, 2020, the ratio initially declined to a low of 5.36 in April 2, 2023. Following this decline, a slight recovery trend is visible, with the ratio rising again to above 5.9 by October 1, 2023. Toward the end of the period, the ratio exhibits some variability, ending at 5.58 as of March 30, 2025. This pattern indicates some inconsistencies in how quickly receivables are collected, with a peak efficiency early on, a gradual weakening, and some improvement in recent periods.
Average Receivable Collection Period (number of days)
The average collection period generally mirrors the inverse pattern of the receivables turnover ratio, ranging from 59 to 68 days. It starts near 60 days in early 2020 and increases to about 65 days by April 4, 2021. This upward trend in days outstanding continues until it peaks around 68 days in April 2, 2023. After reaching this peak, the collection period shows some improvement, declining to about 61 days by October 1, 2023, followed again by an increase toward the end of the timeline, closing at 65 days by March 30, 2025. Overall, this suggests a period of slower collections followed by intermittent enhancements and subsequent deceleration.
Overall Analysis
The data reveals a modest decline in efficiency in accounts receivable management over the initial years, with slower collections reflected in lower turnover ratios and longer collection periods. This deterioration peaks around early 2023. Subsequent quarters display a partial recovery implying efforts to improve collections, but the volatility toward the latest dates suggests that this improvement is not entirely stabilized. Monitoring this metric will be important for understanding ongoing credit and collections effectiveness and cash flow implications.

Operating Cycle

Johnson & Johnson, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Average inventory processing period 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Average receivable collection period 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Short-term Activity Ratio
Operating cycle1 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149
Amgen Inc. 286 276 295 343 409 510 347 349 363 363 351 339 323 305 310 307 306 299
Danaher Corp. 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Eli Lilly & Co. 469 418 441 419 392 395 354 360 367 325 280 284 268 280 282 283 297 352
Gilead Sciences Inc. 159 156 160 172 164 163 169 163 159 162 137 136 132 150 175 180 188 207
Merck & Co. Inc. 212 205 215 221 219 207 203 206 200 182 177 181 199 228 200 192 217 209
Pfizer Inc. 298 288 306 252 242 218 196 206 167 135 160 155 151 159 194 273 362 407
Regeneron Pharmaceuticals Inc. 726 732 734 717 699 677 664 680 700 722 588 511 394 429 562 651 819 802
Thermo Fisher Scientific Inc. 148 142 150 144 142 142 146 146 145 145 148 157 164 168 146 143 147 156
Vertex Pharmaceuticals Inc. 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 163 + 65 = 228

2 Click competitor name to see calculations.

The financial data reveals a consistent upward trend across key operational efficiency metrics over the observed periods.

Average Inventory Processing Period
The average inventory processing period shows a clear increasing pattern from 120 days in early 2021 to a peak of 169 days by mid-2024. Following this peak, a slight reduction occurs, with the metric declining to around 163 days at the end of the observed timeframe. This trend indicates that inventory is being held longer before sale or usage, which could reflect changes in inventory management, supply chain dynamics, or demand fluctuations.
Average Receivable Collection Period
The average receivable collection period experiences modest fluctuations, generally trending upward from 60 days to a high point of 68 days around mid-2023. Thereafter, it decreases somewhat, stabilizing around 61 to 65 days by early 2025. Such variations suggest changes in credit policy effectiveness or customer payment behaviors, with an overall slightly extended collection period compared to the beginning.
Operating Cycle
The operating cycle, representing the total time to convert inventory and receivables into cash, mirrors the increasing trends in inventory and receivables periods. It rises significantly from 180 days in early 2021 to a peak near 236 days by late 2024, before showing a slight decrease towards the end of the timeframe. This elongation of the operating cycle suggests a lengthening cash conversion process, which may impact liquidity and working capital management.

In summary, the metrics indicate a general lengthening of operational timelines, with inventory holding and cash collection taking more time on average. This could imply evolving operational challenges or strategic shifts in working capital policies. The slight decreases observed in the later quarters may reflect efforts to improve efficiency or adapt to market conditions.


Average Payables Payment Period

Johnson & Johnson, average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Payables turnover 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Short-term Activity Ratio (no. days)
Average payables payment period1 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 70 54 61 73 60 69 70 64 73 90 69 72 78 77 67 74 83 84
Bristol-Myers Squibb Co. 104 94 106 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84
Danaher Corp. 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Eli Lilly & Co. 140 140 135 142 127 134 130 138 119 106 86 87 70 83 82 85 97 107
Gilead Sciences Inc. 43 49 49 29 34 31 37 40 41 58 33 31 32 39 40 42 42 67
Merck & Co. Inc. 92 98 86 83 81 89 80 80 84 89 71 75 86 123 80 93 96 108
Pfizer Inc. 110 115 99 79 87 98 72 93 76 72 66 59 55 66 71 98 136 181
Regeneron Pharmaceuticals Inc. 129 146 94 110 137 122 106 116 136 138 98 91 68 84 86 107 164 155
Thermo Fisher Scientific Inc. 44 45 38 37 37 41 35 34 39 48 37 41 46 53 44 41 45 49
Vertex Pharmaceuticals Inc. 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.97 = 123

2 Click competitor name to see calculations.

The analysis of the payables turnover ratio and the average payables payment period reveals distinct fluctuations over the observed periods.

Payables Turnover Ratio

The payables turnover ratio demonstrates variability within a general range of approximately 2.66 to 3.38. The ratio shows a peak around the "Sep 27, 2020" to "Dec 31, 2020" interval where it attained values above 3.3, indicating relatively quicker payment of payables during this time. Following this peak, a downward trend is visible around the "Apr 3, 2022" to "Dec 31, 2022" period, with values declining to a low near 2.66. Subsequently, the ratio exhibits a modest recovery, fluctuating but not returning to the earlier peak levels, ending near 2.97 by "Mar 30, 2025". This pattern suggests some instability or varying payment behavior in managing accounts payable across the quarters.

Average Payables Payment Period

The average payables payment period reflects an inverse relationship with the payables turnover ratio, as expected. Initially observed at around 110 to 122 days in the early periods, this duration notably increases around the "Apr 3, 2022" and "Dec 31, 2022" periods, reaching up to 137 days. This indicates a slower settlement of payables during this timeframe. Afterward, the payment period varies but remains elevated compared to earlier quarters, concluding near 123 days by "Mar 30, 2025". This prolonged average period aligns with the observed decline in payables turnover ratio, suggesting the company took more time, on average, to settle its obligations in recent quarters.

Overall, the data reveals an oscillating pattern in payment practices, with periods of accelerated payable settlements alternating with stretches of more delayed payments. The recent trend indicates an inclination toward longer payment periods, which may reflect strategic cash management decisions or changes in supplier agreements or business conditions during the referenced quarters.


Cash Conversion Cycle

Johnson & Johnson, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Average inventory processing period 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Average receivable collection period 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Average payables payment period 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Short-term Activity Ratio
Cash conversion cycle1 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 216 222 234 270 349 441 277 285 290 273 282 267 245 228 243 233 223 215
Danaher Corp. 84 76 95 90 88 91 98 94 93 81 82 79 75 63 75 75 73 75
Eli Lilly & Co. 329 278 306 277 265 261 224 222 248 219 194 197 198 197 200 198 200 245
Gilead Sciences Inc. 116 107 111 143 130 132 132 123 118 104 104 105 100 111 135 138 146 140
Merck & Co. Inc. 120 107 129 138 138 118 123 126 116 93 106 106 113 105 120 99 121 101
Pfizer Inc. 188 173 207 173 155 120 124 113 91 63 94 96 96 93 123 175 226 226
Regeneron Pharmaceuticals Inc. 597 586 640 607 562 555 558 564 564 584 490 420 326 345 476 544 655 647
Thermo Fisher Scientific Inc. 104 97 112 107 105 101 111 112 106 97 111 116 118 115 102 102 102 107
Vertex Pharmaceuticals Inc. 274 242 229 211 190 166 154 137 131 112 150 120 122 119 144 139 137 114

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 163 + 65123 = 105

2 Click competitor name to see calculations.

Average Inventory Processing Period
The average inventory processing period shows a consistent upward trend over the available quarters. Starting at 120 days in early 2021, it increased steadily to reach a peak of 169 days by mid-2024. Towards the end of the observed period, it slightly decreased but remained elevated around 163 days. This indicates that inventory is being held longer over time, which may suggest slower inventory turnover or changes in inventory management practices.
Average Receivable Collection Period
The receivable collection period fluctuates moderately with no clear long-term trend. It generally oscillates around the low to mid-60-day range, starting at 60 days in early 2021 and rising to a brief high of 68 days in late 2022. It then returns to roughly 60-67 days range through mid-2025. This relative stability suggests consistent credit and collection policies with minor short-term variations.
Average Payables Payment Period
The payables payment period exhibits variability throughout the observed timeline. Initially around 122 days, it declines to a low of about 108-109 days mid-2021, then rises sharply to highs above 130 days at several points, including late 2021 and mid-2023. By the end of the period, it remains elevated around 120-137 days. This pattern may reflect strategic payment timing adjustments or changes in supplier terms.
Cash Conversion Cycle
The cash conversion cycle shows notable volatility across the quarters. It starts at 58 days in early 2021, rises to a peak of 100 days by late 2022, then fluctuates between 72 and 116 days through mid-2025. The upward spikes correspond to periods of increased inventory processing and receivables, suggesting extended time to convert investments in inventory and receivables into cash. The fluctuations indicate variable efficiency in working capital management over time.
Overall Observations
The data reveals a trend of increasing inventory holding periods and variable payment terms to suppliers, which together drive the fluctuations in the cash conversion cycle. The receivable collection period remains relatively stable, implying steady credit management. The prolonged average inventory period and payment delays may impact liquidity dynamics, signaling the need for monitoring to optimize working capital and cash flow efficiency.